Clinical Trials

Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Melanoma, Skin" returned 5 results:

A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
Principal Investigator(s): Philip Friedlander

A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
Principal Investigator(s): Yvonne Saenger

A Single Arm Open-Label Phase II study of Vemurafenib Followed by a Continuous Administration of Ipilimumab in Subjects with Previously Untreated V600 BRAF Mutated Advanced Melanoma
Principal Investigator(s): Yvonne Saenger

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
Principal Investigator(s): Yvonne Saenger

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF for Eligible Patients Participating In Study 005/05
Principal Investigator(s): Yvonne Saenger